4.7 Article

Impact of Oral Immunonutrition on Postoperative Morbidity in Digestive Oncologic Surgery A Nation-wide Cohort Study

期刊

ANNALS OF SURGERY
卷 273, 期 4, 页码 725-731

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/SLA.0000000000003282

关键词

digestive oncology; immunonutrition; morbimortality; surgery

类别

资金

  1. Societe Francaise de chirurgie digestive

向作者/读者索取更多资源

The study, based on a nationwide dataset, found that preoperative immunonutrition did not significantly reduce postoperative morbidity or mortality, but was associated with shorter length of hospital stay.
Objective: The objective of the present study was to assess the effect of preoperative immunonutrition on a nationwide scale. Background: According to international guidelines, immunonutrition should be prescribed before major oncologic digestive surgery to decrease postoperative morbidity. Nevertheless, this practice remains controversial. Methods: We used a prospective national health database named Echantillon generaliste des Beneficiaires. Patients were selected with ICD10 codes of cancer and digestive surgery procedures from 2012 to 2016. Two groups were identified: with reimbursement of immunonutrition 45 days before surgery (IN-group) or not (no-IN-group). Primary outcome was 90-day severe morbidity. Secondary outcomes were postoperative length of stay (LOS) and overall survival. Logistic regression and survival analysis adjusted with IPW method were performed. Results: One thousand seven hundred seventy-one patients were included. The proportion of different cancers was as follows: 72% patients were included in the colorectal group, 14% in the hepato-pancreato-biliary group, and 12% in the upper gastrointestinal group. Patients from the IN-group (n = 606, 34%) were younger (67.1 +/- 11.8 vs 69.2 +/- 12.2 years, P < 0.001), with increased use of other oral nutritional supplements (49.5% vs 31.8%, P < 0.001) and had more digestive anastomoses (89.4% vs 83.0%, P < 0.001). There was no significant difference between the 2 groups for 90-day severe morbidity [odds ratio (OR): 0.91, 95% confidence interval (95% CI): 0.73-1.14] or in survival (hazard ratio: 0.89, 95% CI: 0.73-1.08). LOS were shorter in the IN-group [-1.26 days, 95% CI: -2.40 to -0.10)]. Conclusion: The preoperative use of immunonutrition before major oncologic digestive surgery was not associated with any significant difference in morbidity or mortality. However, the LOS was significantly shorter in the IN-group.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据